Bluebird Bio reborn as Genetix one year after distressed buyout

Approximately one year after a distressed buyout rescued the gene-therapy company Bluebird Bio from financial collapse, the renamed entity Genetix is reporting that it has moved into profit, according to reporting by STAT News. David Meek, who led the acquisition, is credited with restructuring the organisation around its existing approved therapies, which include treatments for sickle cell disease and other serious genetic conditions.

Bluebird Bio had become a cautionary story in biotech: a company that developed scientifically significant gene therapies but failed to achieve commercial viability, facing reimbursement difficulties in the United States and writing off its European operations. The distressed-buyout structure allowed the new leadership to reset the cost base significantly.

The item is behind a STAT+ paywall and full details of Genetix's financial position, pipeline status, and patient access arrangements are not available from the lede alone. The story is nonetheless relevant to those tracking the commercial and policy landscape around gene therapy, and to observers of how approved genetic medicines reach patients after developer instability.